Smarter Drug Sourcing Starts Here
We source, evaluate, and de-risk high-potential assets 10x faster than incumbents.
How Convexia Works
An end-to-end AI stack that replaces months of manual diligence with fast execution.
Asset Discovery Agent
We scan the globe for overlooked drug assets.
From preclinical biotech to abandoned pharma IP, our AI pulls in structured and unstructured data to find high-potential IND-stage candidates.
Scientific Evaluation Stack
We run deep in silico simulations.
Over 50 custom-tuned models assess binding, safety, ADME/PK, immunogenicity, and mechanistic fit.
Specialist Human Review
Experts validate the science.
PhDs with domain expertise review each asset's biology, risks, and translatability before greenlighting it for development.
Market Insight Agent
We model market size, payer risk, and buyer fit.
Every asset gets a Commercial Attractiveness Score (CAS) built from unmet need, disease burden, IP protection, reimbursement signals, pharma portfolio gaps, and other market-shaping factors.
Operational Risk Agent
We score execution risk before trials start.
CRO fragility, CMC complexity, site readiness, and real-world disruption are modeled to flag trial fragility and avoid costly delays.
Business Development Agent
We package and pitch to pharma.
We craft buyer-specific decks, term sheets, and rationale backed by analog deals, targeting buyers with clear strategic fit.
Final Human Review
A live roundtable makes the final call.
Scientific, regulatory, commercial, and clinical leaders align on risk, timing, and exit strategy before making a go/no-go decision.
Explore Our In-Silico Drug Evaluation Stack
We combine 50+ models to assess every asset across molecular, structural, and translational domains.
Protein & Sequence
We use models like ESM-3, ProtBERT, and AlphaFold to simulate structure, conservation, and ligandability at the sequence level.
Docking & Structure
Tools like DiffDock and GNINA model docking poses, binding affinity, and conformational fit without needing a crystal structure.
ADMET Prediction
We run consensus ADMET and safety profiles across 15+ models, flagging hepato-, cardio-, neuro-, and genotoxicity early.
Mechanistic Coherence
We align pathway enrichment, GO terms, and transcriptomic profiles to ensure the MoA is mechanistically sound.
Why Our AI is Different
Built for real-world drug development, not just to say we use AI.
Modular Agents, Not Monolithic Models
Each step of the drug lifecycle is handled by a specialized agent tuned for its specific role.
Human-in-the-Loop by Design
Expert review is integrated into every decision layer, improving accuracy, interpretability, and trust.
Smarter Training with Unlabeled Data
We use semi-supervised learning and synthetic augmentation to train on scarce or unlabeled biomedical data.
Real-World Impact
Pharma market
Convexia sits at the intersection of massive market demand and the need for smarter asset evaluation.
Molecules Screened
Our asset discovery agent continuously scan global databases, patent filings, and preclinical literature across 30+ countries.
Faster Diligence
We cut evaluation timelines from months to days with automated, real-time analysis.
Frequently Asked Questions
We replace siloed, manual workflows with modular AI agents that evaluate assets scientifically, commercially, and operationally - 10x faster and more globally.
We license or acquire early-stage assets and advance them to clinical proof-of-concept. Then we either out-license to pharma or continue development if the upside merits it.
We focus on preclinical to IND-ready assets, especially in solid tumor oncology. Our agents are designed to assess assets before Phase 1 to maximize ROI.
We scan global datasets, including academic tech transfer offices, patent filings, failed trials, and literature, to find overlooked or shelved assets others miss.
Each asset goes through domain-specific review by PhDs and clinicians in oncology, rare disease, immunology, and regulatory affairs before any investment decision.
We don’t operate a wet lab. Instead, we partner with CROs for IND-enabling studies and early trials.
After completing our diligence, we license the asset, work with CROs to advance it through clinical trials, and either pursue acquisition or continue internal development.
We generate revenue through pharma licensing deals, milestone payments, and equity upside in spinouts we co-lead.
We’re backed by Y Combinator and built by Stanford founders with deep experience in regulated health systems, AI infrastructure, and biotech commercialization.
Let's Talk
We're actively seeking collaborators, investors, and discovery partners.